KLRA is a pre-revenue clinical-stage biotech with no earnings to beat — the stock will trade on pipeline catalysts, not quarterly P&L. Key near-term catalysts: ADA 2026 presentations (June 5-8), Jefferies Healthcare Conference (June 4), and Phase 2b high-dose ribupatide data in 2027. The $718.8M IPO cash removes near-term financing risk but the widening net loss is expected for a company scaling clinical trials.
Price Chart
Executive Summary
Kailera Therapeutics reported Q1 2026 financial results with a net loss of $78.9M, widening from $18.0M in Q1 2025, driven by a $60.7M increase in R&D expenses as the company advances four clinical-stage obesity programs. The filing highlights positive clinical data from partner Hengrui across multiple pipeline candidates and the initiation of the global Phase 3 KaiNETIC program for ribupatide injection, with cash runway into mid-2028 following the $718.8M IPO.
Key Financial Metrics
Key Facts
- Net loss of $78.9M for Q1 2026 vs $18.0M in Q1 2025
- R&D expenses of $70.9M, up from $10.1M year-over-year
- Cash, cash equivalents and marketable securities of $581.9M as of March 31, 2026
- Closed $718.8M IPO of 44,921,875 shares at $16.00 per share on April 17, 2026
- Initiated global Phase 3 KaiNETIC program for ribupatide injection (GLP-1/GIP dual agonist)
- Positive Phase 3 topline data for KAI-7535 (oral GLP-1) in type 2 diabetes from partner Hengrui
- Positive Phase 1 data for KAI-4729 (GLP-1/GIP/glucagon tri-agonist) showing 16.0% mean weight loss at 12 weeks
- Cash expected to fund operations into mid-2028
Financial Impact
Net loss widened by $60.9M year-over-year; R&D spend increased 7x to $70.9M; no revenue reported (pre-revenue clinical-stage biotech)
Risk Factors
- No approved products or revenue — entirely dependent on clinical trial success
- Competition from established GLP-1 players (Novo Nordisk, Eli Lilly)
- Reliance on partner Hengrui for key clinical data and regulatory submissions in China
- Phase 3 data for lead candidate ribupatide not expected until 2028 — long wait for pivotal readout
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-239362 |
| Document: ck0002096997-20260526.htm | 0001193125-26-239362 |
| Document: 0001193125-26-239362-index-headers.html | 0001193125-26-239362 |
| Document: 0001193125-26-239362-index.html | 0001193125-26-239362 |
| Document: 0001193125-26-239362.txt | 0001193125-26-239362 |
| 8-K Data (Synthetic) | 0001193125-26-239362 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 9, 2026 23d ago | 3 | $14.91 $12.92 | ▼ −13.35% | ▼ −12.85% | $10.39 (−30.32%) |
Aug 12, 2026 7w ago | 8-K | $17.97 $17.47 | ▼ −2.78% | ▼ −0.82% | $10.39 (−42.18%) |
Jul 31, 2026 9w ago | Court Ruling | $16.94 $18.66 | ▲ +10.15% | ▲ +6.64% | $10.39 (−38.67%) |
Jul 24, 2026 10w ago | Court Ruling | $17.69 $17.05 | ▼ −3.62% | ▼ −3.99% | $10.39 (−41.27%) |
Jun 5, 2026 17w ago | Press Release | $19.70 $19.67 | ▼ −0.15% | ▼ −2.26% | $10.39 (−47.26%) |
May 26, 2026 18w ago | 8-K | $21.91 $22.38 | ▲ +2.15% | ▲ +1.68% | $10.39 (−52.58%) |
May 26, 2026 18w ago | Press Release | $21.91 $22.59 | ▲ +3.10% | ▲ +1.90% | $10.39 (−52.58%) |
May 13, 2026 20w ago | Press Release | $21.11 $19.62 | ▼ −7.06% | ▼ −5.90% | $10.39 (−50.78%) |
Apr 20, 2026 23w ago | 8-K | $25.22 $23.82 | ▼ −5.55% | ▼ −6.63% | $10.39 (−58.80%) |
Apr 20, 2026 23w ago | Insider Cluster | $24.61 $23.51 | ▼ −4.47% | ▼ −5.38% | $10.39 (−57.78%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access